NovaBay Pharmaceuticals Announces New Data on First-in-Class Anti-infective Compounds at ARVO Annual Meeting


NovaBay Pharmaceuticals Announces New Data on First-in-Class
Anti-infective Compounds at ARVO Annual Meeting

EMERYVILLE, Calif. and HUENENBERG, Switzerland, April 30, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (AMEX:NBY) announced today
that the latest public data on its Aganocide(R) compounds, a new class of broad-spectrum antimicrobials, will be presented during three poster
sessions at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Fort Lauderdale, Florida.

NovaBay's Aganocide compounds are first-in-class anti-infectives being developed for the treatment and prevention of antibiotic-resistant
infections. NovaBay and Alcon, Inc., the world's leading eye care company, have a licensing and research collaboration agreement for the
use of NovaBay's Aganocide compounds in the eye, ear and sinus, and forcontact lens care.

The following abstracts will be presented:

"In vitro Microbicidal Activity in Tears of
N,N-dichloro-2,2-dimethyltaurine (NVC-422, AL-46383A), a Novel Topical
Ophthalmic Agent,"


-- Monday, May 3, from 1:45 p.m. to 3:30 p.m.
-- Abstract Authors: Dr. Kathryn Najafi, founder and medical director of
the Eye Institute of Marin and a NovaBay advisor; Dr. Stephen Wilmarth,
NovaBay advisor and a founding member of Medical Vision Technology; and
David Stroman, Ph.D., and Masood Chowhan, Ph.D., of Alcon Laboratories,
et. al.

 

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.